- IBT Key Facts
- Investment Objective
- Investment Policy and Strategy
- Investment Restrictions
- Board of Directors
- Investment Manager / AIFM
- Corporate Advisers
- Banker, Custodian and Administrator
- Corporate Governance
- Shareholder Relations and Voting
- Corporate Calendar
- Annual & Interim Reports
- Legal Information
Board of Directors
The Board are responsible for International Biotechnology Trust plc. The Board of five non-executive Directors sets the Company’s strategy and determines and monitors the Company’s investment objectives and policy. They meet formally five times a year, but also meet informally on other occasions as required. As is appropriate, they have delegated various functions to other parties, the performance of which are regularly reviewed.
Alan Clifton (Chairman)
Alan Clifton was appointed as a non-executive Director of the Company on 21 February 2001 and subsequently as Chairman on 13 April 2012. He was previously the managing director of Morley Fund Management (now Aviva Investors), the asset management arm of Aviva plc, the UK's largest insurance group. He is currently chairman of JPMorgan Japan Smaller Companies Trust plc and of Schroder UK Growth Fund plc, and a director of several other investment companies.
John Aston, OBE
He was appointed as a non-executive Director of the Company on 23 February 2011 and as Chairman of the Audit Committee on 15 April 2011. John Aston was chief Znancial ofZcer of Astex Therapeutics Limited between January 2007 and May 2010, and was chief Znancial ofZcer of Cambridge Antibody Technology for ten years to 2006. Prior to this he was a director in investment banking with Schroders in London and previously worked for British Technology Group and Price Waterhouse. He is a Chartered Accountant and has a degree in Mathematics from Cambridge University. He is currently a director of Polar Capital Global Healthcare Growth and Income Trust plc and a member of the Advisory Board of the CRT Pioneer Fund.
Véronique Bouchet is the founder director of Novudel Associates, a lifesciences consultancy company and VP of business development Europe for Nexus 6 Ltd, a digital health company. Previously she was director of corporate strategy and head of venture capital relations at AstraZeneca PLC. In addition Véronique Bouchet has held a variety of international roles in the healthcare industry across several therapeutic areas and functions, including investment management. She is a non-executive director of Stevenage Bioscience Catalyst, a member of BACIT LP Fund advisory committee, a trustee of Breast Cancer Campaign UK and a member of the Council of Queen Mary, University of London.
She has an MB BS from St Bartholomews's Hospital Medical School and holds a BSc in Psychology from University College London. She has an MBA from INSEAD, and has been awarded the Institute of Directors' Diploma in Company Direction (Distinction).
He was appointed as a non-executive Director of the Company on 25 February 2004. David Clough was director of Research at Roche in the UK between 1986 and 1999. He was responsible for over 300 staff with departments covering chemistry, biology and pre-clinical development. He holds a BSc and PHD in Physiology from The University of Glasgow.
Jim Horsburgh was appointed as a non-executive Director of the Company on 1 February 2013. Jim Horsburgh commenced his career in investment management in 1977, joining Hill Samuel Investment Management as a graduate trainee. He moved to the ICI Pension Fund in 1979 and Abbey Life Assurance Company in 1982, where he managed the company's [agship life and pension equity funds. In 1984 he joined Schroder Investment Manager ("SIM") as UK pension fund manager becoming an account director, a director and in 1998 UK managing director. He left Schroders in 2001 and, following a career break, was chief executive of Witan Investment Trust plc from February 2004 to October 2008.